Immix Biopharma, Inc.

Contributing Author

Recent Articles by Immix Biopharma, Inc.

Oct-05	Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference IMMX GlobeNewswire
Sep-30	Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock IMMX GlobeNewswire
Sep-29	Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock IMMX -8.11% GlobeNewswire
Sep-29	Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis IMMX -8.11% GlobeNewswire
Aug-04	Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference IMMX +10.81% GlobeNewswire
May-22	Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock IMMX GlobeNewswire
May-21	Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock IMMX GlobeNewswire
May-21	Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 IMMX GlobeNewswire
Apr-09	Immix Biopharma to Participate in the Jefferies Global Healthcare Conference IMMX +11.43% GlobeNewswire
Mar-30	Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones IMMX +5.28% GlobeNewswire
Mar-03	Immix Biopharma to Participate in Upcoming Investor Conferences IMMX GlobeNewswire
Jan-28	Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 IMMX GlobeNewswire
Dec-09	Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants IMMX +7.32% GlobeNewswire
Dec-07	Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants IMMX GlobeNewswire
Dec-07	At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
Nov-12	Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch IMMX +15.17% GlobeNewswire
Nov-03	Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 IMMX GlobeNewswire
Oct-14	Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference IMMX GlobeNewswire
Oct-06	Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting IMMX +8.98% IMMX +11.80% GlobeNewswire
Oct-01	Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference IMMX GlobeNewswire
Sep-18	Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 IMMX +6.63% GlobeNewswire
Sep-11	Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors IMMX GlobeNewswire
Sep-08	Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang IMMX IMMX +5.07% GlobeNewswire
Aug-25	Immix Biopharma to Present at the Stifel 2025 Healthcare Conference IMMX GlobeNewswire
Aug-06	Immix Biopharma Announces Other Serious Diseases Strategy IMMX -8.95% IMMX -7.90% GlobeNewswire
Jul-11	Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion IMMX GlobeNewswire
Jul-07	Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
Jun-06	Immix Biopharma Attends FDA CEO Forum in Washington DC IMMX +8.22% GlobeNewswire
Jun-03	Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX -18.85% GlobeNewswire
May-23	Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 IMMX -17.43% GlobeNewswire
May-22	Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX +15.31% GlobeNewswire
May-21	Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis IMMX GlobeNewswire

Immix Biopharma, Inc.

Recent Articles by Immix Biopharma, Inc.

Upgrade your Finviz experience